Radiopharm developer Telix abandons IPO plans in US
2024-06-14
临床3期并购IPO
Just a week after announcing plans for a $200-million debut on NASDAQ, Australian radiopharmaceutical developer Telix Pharmaceuticals has pulled out of the IPO race in the US. The company blamed the decision on “the terms provided under current market conditions.”
Telix was hoping to sell 17 million American depositary shares at a price based on the trading price of its ordinary shares on the Australian stock exchange (ASX). CEO Christian Behrenbruch said Friday that despite “strong interest” from healthcare and specialty biotech funds, the “sticking point in the process was pricing.”
Behrenbruch explained “if we had made the decision to proceed… we would have priced and traded on the basis of a discount to our ASX market capitalisation that was not palatable to management and would have reflected a lack of respect for our existing shareholders.”
Telix added that since the proposed NASDAQ listing wasn't driven by the need to raise capital, management decided not to proceed with the transaction at this time. “While this is not our desired outcome, Telix’s strategic objectives must align with our duty to existing shareholders,” remarked Behrenbruch.
Remains profitable
Telix clarified that it remains profitable, with sufficient finances to support its key objectives, including the commercial launch of its assets Zircaix (Zr-DFO-girentuximab), Pixclara (18F-floretyrosine) and TLX007-CDx in the US, alongside execution of global clinical studies.
The radiopharmaceutical maker further noted that from the time an ‘intention to file’ was announced in January, it has reached significant milestones, including positive clinical readouts, strategic acquisitions of IsoTherapeutics Group, ARTMS, and QSAM Biosciences worth $98.6 million to bolster its manufacturing capacity and pipeline, and two additional FDA approval submissions.
The company’s investigational pipeline boasts TLX591 (177Lu rosopatamab tetraxetan) for prostate cancer, TLX250 (177Lu-DOTA-girentuximab) for renal cancer, TLX101 for glioblastoma, and TLX300 targeting soft tissue sarcoma. Additionally, Telix is testing the QSAM asset Samarium-153-DOTMP to manage pain in pediatric patients with bone metastases or osteosarcoma. Last month, Telix also inked a deal with Bayer to supply Illuccix (TLX591-CDx) for the latter’s Phase III ARASTEP study in prostate cancer.
For more, see - Vital Signs: Mapping the slim pickings in radiopharmaceuticals.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。